A Europe-wide assessment of current medication choices in Huntington's disease

Movement Disorders

Volumn 23, Issue 12, 2008, Pages 1788-

  Priller, Josef ^a   Ecker, Daniel ^b   Landwehrmeyer, Bernhard ^b   Craufurd, David ^c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF ULM   (Germany)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; RISPERIDONE; SERTRALINE; SULPIRIDE; TETRABENAZINE; TIAPRIDE;

AGGRESSION; APATHY; ARTICLE; CULTURAL FACTOR; DECISION MAKING; DEPRESSION; DISEASE REGISTRY; DRUG INDICATION; DRUG USE; DRUG UTILIZATION; EUROPE; GEOGRAPHIC DISTRIBUTION; HUMAN; HUNTINGTON CHOREA; IRRITABILITY; MANIA; MEDICAL PRACTICE; OBSESSIVE COMPULSIVE DISORDER; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOSIS; RIGIDITY; SLEEP DISORDER;

ANTIPSYCHOTIC AGENTS; CHOICE BEHAVIOR; EUROPE; HUMANS; HUNTINGTON DISEASE; PHARMACEUTICAL PREPARATIONS;

EID: 57049139342     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22188     Document Type: Article

References (3)

1. Walker FO. Huntington's disease. Lancet 2007;369:218-228.
2. Bonelli RM, Wenning GK. Pharmacological management of Huntington's disease: an evidence-based review. Curr Pharm Des 2006; 12:2701-2720.
3. Adam OR, Jankovic J. Symptomatic treatment of huntington disease. Neurotherapeutics 2008;5:181-197.